Press Releases

CAMBRIDGE, Mass., Nov 20, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentations at the Piper Jaffray 21st Annual Health Care Conference on Wednesday, December 2, 2009 at 2:00 p.m.

CAMBRIDGE, Mass., Nov 12, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentation at the Lazard Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17, 2009 at 2:40 p.m. EST.

CAMBRIDGE, Mass., Nov 10, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that holders of its 4.75% Convertible Senior Subordinated Notes due 2013 have agreed to exchange approximately $109.0 million in aggregate principal amount of those notes and accrued

• 83% SVR achieved with twice-daily regimen of telaprevir dosed with PEGASYS and ribavirin
• Results highlight the use of response-guided therapy in managing treatment outcomes
• Similar safety and tolerability observed between telaprevir-based regimens dosed either twice daily or three times daily

CAMBRIDGE, Mass., Oct 30, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentations at the Oppenheimer 20 th Annual Healthcare Conference on Wednesday, November 4, 2009 at 2:10 p.m.

• 57% of prior treatment null responder patients achieved an SVR with a 48-week telaprevir-based regimen
• 90% of prior treatment relapsers and 55% of prior treatment partial responders achieved an SVR with 24-week or 48-week telaprevir-based regimens
• Results provide further support for the ongoing Phase 3 registration study, REALIZE, in treatment-failure patients

-Phase 3 registration programs in hepatitis C and cystic fibrosis on track-
-Vertex to present telaprevir SVR data from Study C208 at AASLD meeting this week-

CAMBRIDGE, Mass., Oct 14, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its third quarter 2009 financial results on Monday, October 26, 2009 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.

-Vertex announces plans to initiate a Phase 2 proof-of-concept trial for VX-509 in rheumatoid arthritis-
-Vertex to add $260 million to cash position; company increases guidance for year-end cash position to approximately $800 million and adjusts net loss guidance-
-Vertex announces executive leadership change-

CAMBRIDGE, Mass., Sep 30, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will receive $155 million in cash from two financial transactions. In the first transaction, Vertex will receive approximately $120 million in cash for the issuance of notes

Presentations to include SVR results from Study C208 exploring twice-daily telaprevir-based dosing regimen, final PROVE 3 results and additional sub-analysis of PROVE 1 and PROVE 2 in "difficult-to-cure" patients

-More than 800 Vertex employees take part in service activities at more than 20 nonprofit and community organizations around the globe-
-Several events focused on promoting students' interest in science-
-Day of Service held to honor Vertex founder and long-time CEO Joshua Boger, Ph.D.-

CAMBRIDGE, Mass., Sep 18, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentations at the UBS Global Life Sciences Conference on Tuesday, September 22, 2009 at 2:30 p.m. EDT and at the JMP Securities Healthcare Conference on

CAMBRIDGE, Mass., Sep 03, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentations at the Thomas Weisel Partners 2009 Healthcare Conference on Wednesday, September 9, 2009 at 2:40 p.m.

CAMBRIDGE, Mass., Aug 06, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Canaccord Adams Global Growth Conference on Tuesday, August 11, 2009 at 10:30 a.m. EDT.

- Telaprevir Phase 3 registration program in hepatitis C on track; NDA submission anticipated in second half of 2010 -
- Vertex advancing two drug candidates aimed at the underlying disease mechanism of the orphan disorder cystic fibrosis -
- Vertex ends second quarter with $754 million of cash, cash equivalents and marketable securities; Vertex will add to this position with $105 million of cash through an amended agreement with Mitsubishi Tanabe Pharma Corporation -

-- Vertex to receive $105 million from Mitsubishi following signing, plus the potential for additional milestones upon commercialization ---- Phase 3 registration program for telaprevir in Japan expected to complete enrollment in the third quarter of 2009 --

CAMBRIDGE, Mass., Jul 27, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its second quarter 2009 financial results on Wednesday, August 5, 2009 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.

- Vertex holds rights to earn up to $250 million in milestones associated with filing, approval and launch of telaprevir in Europe -

CAMBRIDGE, Mass., Jul 07, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that Jeffrey Leiden, M.D., Ph.D. and Dennis Winger joined its board of directors. "Jeff and Dennis add tremendous medical and biomedical business perspective to our board.